About US
Contact us
-
ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value from new cancer medsTwo of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals and sales. But a group of Harvard researchers has found another way to me2024/9/13
-
ESMO: Despite positive trial, Merck's Welireg still comes up short in overall survivalOne year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney cancer drug as it continues to show benefits in progression-free survival (2024/9/10
-
Bavarian Nordic eyes external partnerships in bid to produce tens of millions of mpox vaccine dosesAs mpox continues to cause illness and claim lives in Africa, Bavarian Nordic is retooling certain vaccine supply pacts to ensure its vaccine goes to the regions that need it most. At the same time,2024/9/10
-
With another phase 3 win, Gilead races toward 2025 launch for long-acting PrEP drugGilead Sciences is no stranger to making history in HIV. Twelve years after the drugmaker pushed the first pre-exposure prophylaxis (PrEP)HIV med, Truvada, over the FDA finish line, new results from2024/9/5
-
Sanofi completes build out of $554M pandemic-ready modular plant for vaccines, biologicsAn ambitious project that was hatched during the coronavirus pandemic has hit a key milestone as Sanofi has completed construction of Modulus, a vaccine and biological medicine plant that can be quic2024/9/5
-
Intercept's Ocaliva approval in jeopardy after FDA flags concerns in advisory committee briefing docFor Intercept Pharmaceuticals’ beleaguered liver disease drug Ocaliva, the hits just keep coming. Ahead of an advisory committee meeting slated for Friday, the FDA on Wednesdayunleashed damningbriefi2024/9/3
-
India's Zydus hit with warning letter as FDA flags glass contamination concerns and moreLast week, Zydus Lifesciences confirmed the receipt of an FDA warning letter at its Waghodia plant in Gujarat, India, marking the latest in a string of production reprimands for the Indian drugmaker.2024/9/3
-
Sanofi, Regeneron to seek approval for Dupixent in bullous pemphigoid after positive phase 3 studySanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. On the same day the companiesunveiled positive datafrom a study in chronic spontaneous urticaria (CSU) and anew an2024/8/29
-
After FDA rejection, Sanofi and Regeneron show data that could pave way for Dupixent to treat hives conditionEleven months after sustaining arejectionfrom the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and Regeneron have presented data from a phase 3 trial that could help push the2024/8/29
-
Gilead's Trodelvy triplet underwhelms, but exec says data bolster company's phase 3 lung cancer designGilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks like that win won’t come from a triplet regimen that combines the antibody-dr2024/8/27